BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
for Hypertension
Sites in Philadelphia, Doylestown +54 more locations
Sponsor: Orchestra BioMed, Inc
Sex: All·Age: 18+
Code: NCT06059638·Recruiting·Listed Sep 2023
Paid Clinical Trials in Pennsylvania
Pennsylvania has 3,479 paid clinical trials enrolling now across cities including Philadelphia, Pittsburgh and Hershey. Search by condition, age, or phase to find compensated research studies accepting participants near you.
Research sites in Pennsylvania include Penn Medicine, Children's Hospital of Philadelphia and UPMC, running studies across oncology, cardiology, neurology, and more. Both patients and healthy volunteers may qualify. Most studies offer compensation for time and travel.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Filter results
3,012 clinical trials
Get a weekly email when new trials open in Philadelphia, PA.
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
for Chronic Kidney Disease
Drug: Empagliflozin
Sites in Philadelphia +26 more locations
Sponsor: Boehringer Ingelheim
Sex: All·Age: 2 - 17
Code: NCT07107945·Phase 3·Recruiting·Listed Aug 2025
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
for Neoplasms
Sites in Philadelphia, Pittsburgh +76 more locations
Sponsor: Celgene
Sex: All·Age: All ages
Code: NCT03435796·Phase 2, Phase 3·Recruiting·Listed Feb 2018
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
for Obstructive Hypertrophic Cardiomyopathy
Drug: Mavacamten
Sites in Pittsburgh, Bethlehem +46 more locations
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 18+
Code: NCT05489705·Recruiting·Listed Aug 2022
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
for Refractory Angina
Sites in Pittsburgh +65 more locations
Sponsor: Shockwave Medical, Inc.
Sex: All·Age: 18+
Code: NCT05102019·Recruiting·Listed Nov 2021
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
for Focal Epilepsy
Drug: BHV-7000
Sites in Philadelphia, Pittsburgh +43 more locations
Sponsor: Biohaven Therapeutics Ltd.
Sex: All·Age: 18 - 75
Code: NCT06132893·Phase 2, Phase 3·Recruiting·Listed Nov 2023
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
for Breast Neoplasms
Sites in Philadelphia, Pittsburgh +36 more locations
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 18+
Code: NCT06926868·Phase 2, Phase 3·Recruiting·Listed Apr 2025
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
for Leukemia, Myeloid, Acute
Drug: Venetoclax
Sites in Philadelphia, Pittsburgh +54 more locations
Sponsor: Janssen Research & Development, LLC
Sex: All·Age: 18+
Code: NCT06852222·Phase 3·Recruiting·Listed Feb 2025
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
for Low Grade Serous Ovarian Cancer
Drug: Avutometinib
Sites in Philadelphia, Pittsburgh +34 more locations
Sponsor: Verastem, Inc.
Sex: Female·Age: 18+
Code: NCT06072781·Phase 3·Recruiting·Listed Oct 2023
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
for Primary Biliary Cholangitis
Sites in Philadelphia, Pittsburgh +50 more locations
Sponsor: Gilead Sciences
Sex: All·Age: 18+
Code: NCT06051617·Phase 3·Recruiting·Listed Sep 2023
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
for Parkinson Disease
Sites in Philadelphia +44 more locations
Sponsor: Neuron23 Inc.
Sex: All·Age: 40 - 80
Code: NCT06680830·Phase 2·Recruiting·Listed Nov 2024
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
for Depressive Disorder, Major
Drug: Seltorexant
Sites in Philadelphia +43 more locations
Sponsor: Janssen Research & Development, LLC
Sex: All·Age: 18 - 74
Code: NCT06559306·Phase 3·Recruiting·Listed Aug 2024
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
for Multiple Myeloma
Sites in Philadelphia, Pittsburgh +26 more locations
Sponsor: Janssen Research & Development, LLC
Sex: All·Age: 18+
Code: NCT05201781·Phase 4·Recruiting·Listed Jan 2022
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
for Glioma
Sites in Philadelphia, Pittsburgh +44 more locations
Sponsor: Nuvation Bio Inc.
Sex: All·Age: 18+
Code: NCT05303519·Phase 3·Recruiting·Listed Mar 2022
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
for Carcinoma, Non-Small-Cell Lung
Drug: Intismeran autogene
Sites in Bethlehem +49 more locations
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06623422·Phase 3·Recruiting·Listed Oct 2024
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
for Heart Failure
Sites in Philadelphia, Abington +30 more locations
Sponsor: Procyrion
Sex: All·Age: 21+
Code: NCT05677100·Recruiting·Listed Jan 2023
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
for Non-small Cell Lung Cancer
Drug: Intismeran autogene
Sites in Philadelphia +57 more locations
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06077760·Phase 3·Recruiting·Listed Oct 2023
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
for Non-Small Cell Lung Cancer
Sites in Philadelphia, Pittsburgh +24 more locations
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 18+
Code: NCT07100080·Phase 2, Phase 3·Recruiting·Listed Aug 2025
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
for Mantle Cell Lymphoma
Drug: Sonrotoclax
Sites in Hershey, West Reading +39 more locations
Sponsor: BeOne Medicines
Sex: All·Age: 18+
Code: NCT06742996·Phase 3·Recruiting·Listed Dec 2024
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
for Episodic Migraine
Drug: Xeomin
Sites in Philadelphia +46 more locations
Sponsor: Merz Therapeutics GmbH
Sex: All·Age: 18+
Code: NCT07018700·Phase 3·Recruiting·Listed Jun 2025
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
for Chronic Migraine
Drug: Xeomin
Sites in Philadelphia +47 more locations
Sponsor: Merz Therapeutics GmbH
Sex: All·Age: 18+
Code: NCT07018713·Phase 3·Recruiting·Listed Jun 2025
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
for Major Depressive Disorder
Sites in Philadelphia, Allentown +28 more locations
Sponsor: Syndeio Biosciences, Inc
Sex: All·Age: 18 - 64
Code: NCT07115329·Phase 2·Recruiting·Listed Aug 2025
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
for Crohn's Disease
Drug: Ustekinumab
Sites in Wexford +40 more locations
Sponsor: Takeda
Sex: All·Age: 18 - 70
Code: NCT06045754·Phase 4·Recruiting·Listed Sep 2023
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
for Multiple Myeloma
Drug: Daratumumab
Sites in Pittsburgh, Hershey +64 more locations
Sponsor: Janssen Research & Development, LLC
Sex: All·Age: 18+
Code: NCT05552222·Phase 3·Recruiting·Listed Sep 2022
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
for Pancreatic Ductal Adenocarcinoma
Sites in Pittsburgh +24 more locations
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT06586515·Phase 1·Recruiting·Listed Sep 2024
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
for Pancreatic Neuroendocrine Tumor (pNET)
Sites in Philadelphia, Pittsburgh +38 more locations
Sponsor: Exelixis
Sex: All·Age: 18+
Code: NCT06943755·Phase 2, Phase 3·Recruiting·Listed Apr 2025
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
for Non-Small Cell Lung Cancer
Drug: Divarasib
Sites in Pittsburgh, Bethlehem +52 more locations
Sponsor: Hoffmann-La Roche
Sex: All·Age: 18+
Code: NCT06793215·Phase 3·Recruiting·Listed Jan 2025
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
for Moderately to Severely Active Crohns Disease
Drug: Afimkibart
Sites in Hershey, Uniontown +90 more locations
Sponsor: Hoffmann-La Roche
Sex: All·Age: 16 - 80
Code: NCT06819878·Phase 3·Recruiting·Listed Feb 2025
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
for Ulcerative Colitis
Drug: Tofacitinib
Sites in Wexford +36 more locations
Sponsor: Takeda
Sex: All·Age: 18 - 65
Code: NCT06095128·Phase 4·Recruiting·Listed Oct 2023
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
for Metastatic Breast Cancer
Drug: Zongertinib
Sites in Hershey +25 more locations
Sponsor: Boehringer Ingelheim
Sex: All·Age: 18+
Code: NCT06324357·Phase 1, Phase 2·Recruiting·Listed Mar 2024
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
for Primary Generalized Tonic-Clonic Seizures
Drug: XEN1101
Sites in Philadelphia, Pittsburgh +46 more locations
Sponsor: Xenon Pharmaceuticals Inc.
Sex: All·Age: 12+
Code: NCT05667142·Phase 3·Recruiting·Listed Dec 2022
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
for Geographic Atrophy
Sites in Erie +54 more locations
Sponsor: Astellas Pharma Global Development, Inc.
Sex: All·Age: All ages
Code: NCT06779773·Recruiting·Listed Jan 2025
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
for Ovarian Cancer
Sites in Pittsburgh +34 more locations
Sponsor: Merck Sharp & Dohme LLC
Sex: Female·Age: 18+
Code: NCT06824467·Phase 3·Recruiting·Listed Feb 2025
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
for High Grade Epithelial Ovarian Cancer
Sites in Pittsburgh, Doylestown +35 more locations
Sponsor: Genmab
Sex: All·Age: 18+
Code: NCT05579366·Phase 1, Phase 2·Recruiting·Listed Oct 2022
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
for Ovarian Cancer
Drug: INCB123667
Sites in Hershey +37 more locations
Sponsor: Incyte Corporation
Sex: Female·Age: 18 - 99
Code: NCT07023627·Phase 2·Recruiting·Listed Jun 2025
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
for DLBCL
Sites in Horsham +16 more locations
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT05139017·Phase 2, Phase 3·Recruiting·Listed Dec 2021
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
for Small-cell Lung Cancer
Drug: ZL-1310
Sites in Pittsburgh, Media +30 more locations
Sponsor: Zai Lab (Shanghai) Co., Ltd.
Sex: All·Age: 18+
Code: NCT07218146·Phase 3·Recruiting·Listed Oct 2025
Pelacarsen Roll-over Extension Program
for Atherosclerotic Cardiovascular Disease
Drug: Pelacarsen
Sites in Easton, Linwood +73 more locations
Sponsor: Novartis Pharmaceuticals
Sex: All·Age: 18 - 100
Code: NCT06875973·Phase 3·Recruiting·Listed Mar 2025
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
for Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Drug: Avacopan
Sites in Philadelphia, Pittsburgh +56 more locations
Sponsor: Amgen
Sex: All·Age: 18 - 100
Code: NCT06072482·Phase 4·Recruiting·Listed Oct 2023
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
for Coronary Arterial Disease (CAD)
Sites in York, Mechanicsburg +44 more locations
Sponsor: Boston Scientific Corporation
Sex: All·Age: 18+
Code: NCT06959524·Recruiting·Listed May 2025